Literature DB >> 15057192

Update: Cutaneous leishmaniasis in U.S. military personnel--Southwest/Central Asia, 2002-2004.

.   

Abstract

Cutaneous leishmaniasis (CL) is a sand fly-borne parasitic infection. Preliminary data about cases of CL in military personnel deployed to three countries (Afghanistan, Iraq, and Kuwait) in Southwest/Central Asia have been published previously. During August 2002-February 2004, Department of Defense (DoD) staff identified 522 parasitologically confirmed cases of CL in military personnel. Leishmania major was the etiologic agent for all 176 cases for which species data, obtained by isoenzyme electrophoresis of cultured parasites, are available. This update focuses on the 361 cases (69% of 522) in patients whose demographic data were collected systematically under treatment protocols for therapy with the pentavalent antimonial compound sodium stibogluconate (Pentostam(R); GlaxoSmithKline, United Kingdom) at Walter Reed Army Medical Center, District of Columbia. U.S. health-care providers should consider CL in persons with persistent skin lesions who were deployed to Southwest/Central Asia or who were in other areas where leishmaniasis is endemic.

Entities:  

Mesh:

Year:  2004        PMID: 15057192

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  13 in total

1.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment.

Authors:  Jonathan Berman
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

3.  Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

Authors:  Yoav Keynan; Oscar E Larios; Marni C Wiseman; Marie Plourde; Marc Ouellette; Ethan Rubinstein
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

4.  Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network.

Authors:  T Weitzel; N Mühlberger; T Jelinek; M Schunk; S Ehrhardt; C Bogdan; K Arasteh; T Schneider; W V Kern; G Fätkenheuer; G Boecken; T Zoller; M Probst; M Peters; T Weinke; S Gfrörer; H Klinker; M-L Holthoff-Stich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

5.  Highly sensitive nested polymerase chain reaction to improve the detection of Leishmania species in clinical specimens.

Authors:  Hassan Mohammad Tawfeeq; Shahnaz AbdulKader Ali
Journal:  J Parasit Dis       Date:  2022-05-13

Review 6.  Gulf war servicemen and servicewomen: the long road home and the role of health care professionals to enhance the troops' health and healing.

Authors:  Robin B McFee
Journal:  Dis Mon       Date:  2008-05       Impact factor: 3.800

7.  Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Authors:  Thomas P C Dorlo; Pieter P A M van Thiel; Alwin D R Huitema; Ron J Keizer; Henry J C de Vries; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

8.  Cutaneous and presumed visceral leishmaniasis in a soldier deployed to Afghanistan.

Authors:  James P Woodrow; Joshua D Hartzell; Jim Czarnik; David M Brett-Major; Glenn Wortmann
Journal:  MedGenMed       Date:  2006-11-30

9.  Dermatology and HIV/AIDS in Africa.

Authors:  Jenny Hu; Karen McKoy; Art Papier; Sidney Klaus; Terence Ryan; Henning Grossman; Elisante J Masenga; Aisha Sethi; Noah Craft
Journal:  J Glob Infect Dis       Date:  2011-07

10.  Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629].

Authors:  Sandra Y Silva; Ligia C Rueda; Marcos López; Iván D Vélez; Christian F Rueda-Clausen; Daniel J Smith; Gerardo Muñoz; Hernando Mosquera; Federico A Silva; Adriana Buitrago; Holger Díaz; Patricio López-Jaramillo
Journal:  Trials       Date:  2006-05-15       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.